Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus
Kate M. Moore(Queen Mary University of London), John F. Marshall(Queen Mary University of London)
Cited by 49
Related Papers
The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy
|The Journal of Pathology|2019|109
Integrin-αvβ6 targeted peptide-toxin therapy in a novel αvβ6-expressing immunocompetent model of pancreatic cancer
|Pancreatology|2024|12
Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model
|Exploration of Targeted Anti-tumor Therapy|2022|1